Urge your members of Congress to support continued medical research funding
ASH, the world's
largest professional society concerned with the causes and treatments of blood
disorders, regularly issues press releases highlighting clinical and research
advances announced at the ASH annual meeting and published
in Blood, as well as releases and statements on breaking policy news
affecting the field of hematology.
Need to speak with an expert? Complete our Request An Expert form.
To be added to ASH's press release distribution list, contact Stephen Fitzmaurice at firstname.lastname@example.org.
New data indicates that an investigational treatment that mimics a key clotting enzyme is effective, safe, and may one day eliminate the need for blood products for people with the rare, life-threatening blood disease hereditary thrombotic thrombocytopenic purpura.
ASH today announced the names of 25 hematologists and medical professionals from developing countries selected to participate in the 2017 ASH Visitor Training Program (VTP). Participants will receive up to 12 weeks of specialized hematology training at host institutions in many different parts of the world.
ASH's President issued this response to today's approval by the U.S. FDA of the first chimeric antigen receptor (CAR) T-cell therapy for the treatment of children with relapsed/treatment-resistant CD-19 positive acute lymphocytic leukemia (ALL).
Urge your members of Congress to support continued medical research funding.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology